KML29 is a potent and selective monoacylglycerol lipase (MAGL) inhibitor, effective across human, mouse, and rat enzymes while showing no activity against FAAH. It selectively elevates brain 2-AG levels in vivo, making it a valuable research tool for studying endocannabinoid signaling in neurological and inflammatory disease models.